Home › Newron Receives Complete Response Letter From US FDA For Xadago (safinamide)
 

Keywords :   


Newron Receives Complete Response Letter From US FDA For Xadago (safinamide)

2016-03-30 07:24:45| drugdiscoveryonline Home Page

Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partners Zambon S.p.A. and US WorldMeds announced recently that a complete response letter from the FDA has been received for safinamide

Tags: complete response letter receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Atlantic Tropical Weather Outlook
05.10Eastern North Pacific Tropical Weather Outlook
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
More »